What questions should be included in a follow‑up assessment for a patient with schizoaffective disorder, bipolar type, and for a patient with schizophrenia?

Follow-Up Assessment Questions for Schizoaffective Disorder (Bipolar Type) and Schizophrenia

Both diagnoses require systematic monitoring of symptom control, medication adherence, side effects, cardiometabolic health, and suicide/violence risk at every follow-up visit, with schizoaffective bipolar type requiring additional assessment of mood episode features and higher vigilance for violent behavior during psychotic episodes.

Core Assessment Domains (Both Diagnoses)

Symptom Monitoring

Ask about specific symptom domains using quantitative measures 1:

• Positive symptoms: Hallucinations, delusions, disorganized speech (frequency, intensity, impact on functioning)
• Negative symptoms: Social withdrawal, avolition, flat affect, anhedonia
• Cognitive symptoms: Memory problems, concentration difficulties, executive function impairment
• Functional impairment: Work/occupation status, social relationships, self-care abilities

The APA guidelines explicitly recommend using quantitative measures to track symptom severity and functional impairment at each visit 1.

Medication Assessment

Directly assess adherence and effectiveness 2, 1:

• "Are you taking your medication as prescribed?" (non-adherence is significantly higher in schizoaffective disorder at 19% vs lower rates in other psychotic disorders) 3
• "Have you missed any doses in the past week/month?"
• "Are your symptoms better, worse, or the same since last visit?"
• "What side effects are you experiencing?"

For patients with poor adherence history, specifically discuss long-acting injectable antipsychotics as an option 1.

Cardiometabolic Monitoring

Obtain these measurements at specified intervals 2:

At each visit (or as scheduled):

• BMI and waist circumference (weekly × 6 weeks after starting/switching antipsychotics, then at 3 months, then annually)
• Blood pressure (same schedule)

Laboratory monitoring:

• Fasting glucose or HbA1c (4 weeks after initiation, then 3 months, then annually)
• Lipid panel (3 months, then annually)
• Liver function tests (3 months, then annually)
• Prolactin if symptomatic
• Renal function and electrolytes (annually)
• Full blood count (annually)
• Vitamin B12 if on metformin (annually) 2

Safety Assessment

Ask directly about self-harm and violence 1, 4:

• "Have you had thoughts of hurting yourself or ending your life?"
• "Have you made any plans or attempts?"
• "Have you had thoughts of hurting others?"
• "Have you engaged in any violent or aggressive behavior?"

This is critical: Schizoaffective disorder shows 12-fold higher rates of violent behavior during psychotic episodes compared to bipolar disorder, while bipolar disorder shows 13-fold higher suicide attempt rates 4. Both require systematic assessment at every visit.

Substance Use

Screen for tobacco and other substances 1:

• Current tobacco use (contributes significantly to mortality)
• Alcohol use
• Cannabis and other illicit substances

Anticholinergic Burden

Review all medications for anticholinergic effects 2:

• Ask about dry mouth, constipation, urinary retention, blurred vision, confusion
• Clozapine, olanzapine, and quetiapine have highest central anticholinergic activity
• Consider dose reduction if cognitive symptoms worsen

Additional Questions Specific to Schizoaffective Disorder, Bipolar Type

Mood Episode Assessment

Systematically assess for manic and depressive features:

Manic symptoms:

• "Have you felt unusually energetic, euphoric, or irritable?"
• "Have you needed less sleep than usual?"
• "Have you been more talkative or had racing thoughts?"
• "Have you engaged in risky behaviors (spending, sexual activity, substance use)?"
• "Have you had grandiose thoughts or beliefs?"

Depressive symptoms:

• "How has your mood been—sad, empty, or hopeless?"
• "Have you lost interest or pleasure in activities?"
• "How is your sleep and appetite?"
• "Do you feel worthless or excessively guilty?"
• "How is your energy level?"

Temporal Relationship of Symptoms

This is diagnostically crucial 5:

• "When you have psychotic symptoms (hallucinations/delusions), do they only occur during mood episodes, or do they persist even when your mood is stable?"
• Document whether psychotic symptoms occur independently of mood episodes for ≥2 weeks

Important caveat: Research shows diagnostic shift from bipolar disorder to schizoaffective disorder occurs when psychotic symptoms become persistent and unrelated to mood episodes, with mean time to shift of 9 years 6. Reassess diagnosis longitudinally.

Violence Risk During Psychotic Episodes

Specifically assess for hetero-aggressive behavior 4:

• "During times when you're experiencing hallucinations or delusions, have you felt the need to protect yourself or act on commands?"
• "Have you gotten into physical altercations?"

Schizoaffective patients show significantly higher rates of violent behavior during psychotic episodes compared to bipolar patients (HR=12.0) 4.

Additional Questions Specific to Schizophrenia

Duration and Persistence of Psychotic Symptoms

Focus on chronicity without mood component:

• "How often do you experience hallucinations or delusions?"
• "Are these symptoms present most of the time, or do they come and go?"
• Document continuous or near-continuous presence of psychotic symptoms

Treatment Resistance Assessment

If symptoms persist despite adequate trials 1:

• "Have you tried at least two different antipsychotic medications at adequate doses for adequate duration?"
• If yes, clozapine should be offered (1B recommendation for treatment-resistant schizophrenia)

Negative Symptom Burden

Schizophrenia typically has more prominent negative symptoms:

• "How much time do you spend with others?"
• "What activities do you engage in during the day?"
• "Do you feel motivated to do things?"
• "Do you experience pleasure from activities you used to enjoy?"

Monitoring Frequency and Relapse Prevention

Schizoaffective patients relapse earlier with higher hospitalization rates (24.8% vs 12.3% in bipolar disorder over 12 months, with mean days to hospitalization of 312 vs 338 days) 4. This necessitates:

• More frequent follow-up visits for schizoaffective patients, particularly in the first year
• Close monitoring of self- and hetero-aggression symptoms can delay hospitalizations 4
• Higher treatment intensity at baseline (patients without relapses had significantly higher mean number of treatments) 4

Common Pitfalls to Avoid

1. Assuming diagnostic stability: Diagnostic shift from bipolar to schizoaffective occurs in some patients over years; reassess diagnosis if psychotic symptoms become chronic and mood-independent 6, 7

2. Neglecting cardiometabolic monitoring: This is a major contributor to the 15-20 year reduced life expectancy in these populations 1

3. Underestimating non-adherence: Schizoaffective disorder shows significantly higher non-adherence rates; consider long-acting injectables proactively 3

4. Missing the temporal relationship: The hallmark of schizoaffective disorder is psychotic symptoms occurring for ≥2 weeks in the absence of major mood episodes 5

5. Inadequate safety assessment: Both diagnoses carry elevated suicide risk (4-10% lifetime), with different patterns (suicide attempts higher in bipolar features, violence higher in schizoaffective) 1, 4